| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3586 |
| Trial ID | NCT06043323 |
| Disease | Follicular Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Axi-Cel|Relma-cel|Axicabtagene Ciloleucel|JWCAR029|relmacabtagene autoleucel|Yescarta |
| Co-treatment | Prednisone|Diphenhydramine|Acetaminophen |
| Location approved | China |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma |
| Year | 2024 |
| Country | United States |
| Company sponsor | M.D. Anderson Cancer Center |
| Other ID(s) | 2023-0087 |
| Cohort 1 | |||||||||
|
|||||||||